Sector pending / Pharmaceutical PreparationsUpdated 2026-05-10 22:07 UTC

FRA/354 stock hub

FRA/354 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/354is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/354FRA/354

—

Loading chart…

In the news

Latest news · FRA/354

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E4.1

P25 n/aP50 n/aP75 n/a

Trailing P/E16

P25 n/aP50 n/aP75 n/a

ROE27.4

P25 n/aP50 n/aP75 n/a

ROIC16.8

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/354 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

201

Groups with data

Currency

USD

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	423
Employees Change	160%
Employees Change Percent	81.22
Enterprise value	EUR 1.5B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Pharmaceutical Preparations
Last refreshed	2026-05-10
Market cap	EUR 1B
Price	EUR 33
Price currency	EUR
Rev Per Employee	1,632,758.89x
Sic	2834
Symbol	fra/354
Website	https://www.collegiumpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	6.25%
EV Earnings	22.65x
EV/EBIT	8.53x
EV/EBITDA	3.99x
EV/FCF	5.15x
EV/Sales	2.18x
FCF yield	27.49%
Forward P/E	4.05x
P/B ratio	3.84x
P/E ratio	16.01x
P/S ratio	1.51x
PE Ratio3 Y	23.85x
PE Ratio5 Y	20.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	25.5%
EBITDA Margin	53.81%
FCF margin	41.42%
Gross margin	89.61%
Gross Profit	EUR 618.9M
Gross Profit Growth	24.15%
Gross Profit Growth Q	10.52%
Gross Profit Growth3 Y	17.28%
Gross Profit Growth5 Y	22.04%
Net Income	EUR 65M
Net Income Growth	70.75%
Net Income Growth Q	499.75%
Net Income Growth5 Y	12.3%
Pretax Margin	13.59%
Profit Margin	9.41%
Profit Per Employee	EUR 153,672
ROA	7.73
Roa5y	6.05
ROCE	16.69
ROE	27.41
Roe5y	21.04
ROIC	16.82
Roic5y	12.84

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	38.69%
Cagr3y	17%
Cagr5y	12.89%
EPS Growth	58.63
EPS Growth Q	471.4
EPS Growth5 Y	11.06
FCF Growth	67.8%
FCF Growth Q	4.11%
FCF Growth3 Y	23.4%
FCF Growth5 Y	23.23%
OCF Growth	66.82%
OCF Growth Q	3.1%
OCF Growth3 Y	23.16%
OCF Growth5 Y	22.26%
Revenue Growth	19.88x
Revenue Growth Q	8.87x
Revenue Growth3 Y	14.9x
Revenue Growth5 Y	19.91x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.49
Assets	EUR 1.4B
Cash	EUR 365.8M
Current Assets	EUR 632.3M
Current Liabilities	EUR 368.8M
Debt	EUR 806.3M
Debt EBITDA	EUR 2.14
Debt Equity	EUR 2.98
Debt FCF	EUR 2.82
Equity	EUR 271M
Interest Coverage	2.62
Liabilities	EUR 1.2B
Long Term Assets	EUR 800.4M
Long Term Liabilities	EUR 792.9M
Net Cash	EUR -440.5M
Net Cash By Market Cap	EUR -42.33
Net Debt EBITDA	EUR 1.19
Net Debt Equity	EUR 1.63
Net Debt FCF	EUR 1.54
Tangible Book Value	EUR -388.2M
Tangible Book Value Per Share	EUR -11.98

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.71
Inventory Turnover	2.07
Net Working Capital	EUR -66.8M
Quick ratio	1.5
Working Capital	EUR 269.5M
Working Capital Turnover	EUR 3.93

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-8.45%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	38.66%
200-day SMA	33.48
3Y total return	60.19%
50-day SMA	30.09
50-day SMA vs 200-day SMA	50under200
5Y total return	83.33%
All Time High	42
All Time High Change	-21.43%
All Time High Date	2025-12-29
All Time Low	6.8
All Time Low Change	385.01%
All Time Low Date	2017-05-09
ATR	0.73
Ch YTD	-21.05
High	33
High52	42
High52 Date	2025-12-29
High52ch	-21.43%
Low	33
Low52	23.8
Low52 Date	2025-05-08
Low52ch	38.66%
Ma50ch	9.68%
Price vs 200-day SMA	-1.45%
RSI	70.55
RSI Monthly	53.25
RSI Weekly	49.57
Sharpe ratio	0.87x
Sortino ratio	1.51
Total Return	-8.45%
Tr YTD	-21.05
Tr1m	18.71%
Tr1w	14.58%
Tr3m	-16.67%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 176.1M
Operating Income Growth	18.72
Operating Income Growth Q	26.74
Operating Income Growth3 Y	14.72
Operating Income Growth5 Y	22.92
Operating margin	25.5

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	32,035,098%
Net Borrowing	-52,138,639.5
Shares Insiders	1.11%
Shares Institutions	117.1%
Shares Qo Q	-0.03%
Shares Yo Y	8.45%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 250.3M
Average Volume	4.95x
Bv Per Share	8.36
CAPEX	EUR -1.1M
Ch1m	18.71
Ch1w	14.58
Ch1y	38.66
Ch3m	-16.67
Ch3y	60.19
Ch5y	83.33
Ch6m	-5.71
Change	7.84%
Change From Open	0
Close	30.6
Days Gap	7.84
Depreciation Amortization	191,169,641.1
Earnings Date	2026-05-07
EBIT	EUR 176.1M
EBITDA	EUR 371.7M
EPS	EUR 1.73
F Score	8
FCF	EUR 286.1M
FCF EV Yield	19.43x
Financing CF	-92,238,222
Fiscal Year End	December
Founded	2,002
Goodwill	123,738,854.9
Graham Number	19.96106
Graham Upside	-39.51
Income Tax	EUR 28.9M
Investing CF	-45,294,743
Is Primary Listing	0
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Lynch Fair Value	EUR 25.35
Lynch Upside	-23.18
Ma150	34.54
Ma150ch	-4.45%
Ma20	28.92
Ma20ch	14.11%
Net CF	149,576,293
Open	33
P FCF Ratio	3.64
P OCF Ratio	3.62
Ppne	13,258,733.8
Price Date	2026-05-08
Price EBITDA	EUR 2.8
Relative Volume	20x
Revenue	690,657,009x
SBC By Revenue	5.18x
Share Based Comp	35,786,533
Tax By Revenue	4.18x
Tax Rate	30.75%
Tr6m	-5.71%
Volume	0

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/354 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/354 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/354?

Insider, institutional, and short-interest positioning.

Institutional ownership

+117.1%

Share of float held by funds and institutions

Insider ownership

+1.1%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+8.4%

Negative means the company is buying back shares.

Technical

FRA/354 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

70.5

Above 70: short-term overbought

Price vs 200-day MA

-1.4%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.87

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/354

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/354 stock rating?

fra/354 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/354 analysis?

The full report lives at /stocks/fra/354/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/354?

The latest report frames fra/354 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/354 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.